RUBY
Rubius Therapeutics, Inc.
Set alert
- Open
- 0.0555
- Prev close
- 0.057
- Mkt cap
- 0
- Vol
- 755.86K
- Avg vol
- 99.53K
- EPS
- -1.99
- P/E
- -0.03
- Div yield
- 0.00%
More statistics
- Low
- 0.055
- High
- 0.057
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 3, 2024
- 50-d avg
- 0.00
- 200-d avg
- 0.00
News
3 months ago prnewswire.com
SEABOURN UNVEILS DETAILS OF 'THE RUBY COLLECTION': 54 VOYAGES ACROSS OCEAN AND EXPEDITION FOR ITS 40TH ANNIVERSARY IN 2028
Key Points Seabourn's Ruby Collection features 54 voyages in 2028 across its five-ship ocean and expedition fleet, commemorating the line's 40th anniversary, or "Ruby Jubilee." Voyages span the…
2 years ago globenewswire.com
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 36 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 135 companies reached new 52-week lows.
3 years ago investorplace.com
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
Rubius Therapeutics (NASDAQ: RUBY ) stock is heading higher on Tuesday despite a lack of news from the cellular medicines company. Instead, it looks like increasing interest from traders is behind…
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
3 years ago investorplace.com
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
Rubius Therapeutics (NASDAQ: RUBY ) stock is falling hard on Tuesday after the biotechnology company received a Nasdaq delisting notice. According to a filing with the U.S. Securities and Exchange…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 298 companies achieved new lows for the year.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday saw 219 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 72 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 283 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 120 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 413 companies reached new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 446 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 838 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 402 companies made new 52-week lows.
4 years ago pennystocks.com
Hot Penny Stocks to Buy This Week? 3 to Watch Now
Which penny stocks are you watching today? The post Hot Penny Stocks to Buy This Week?
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 1076 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 429 stocks made new 52-week lows.
4 years ago globenewswire.com
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red…
-
4 years ago benzinga.com
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 574 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday
Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.
-
4 years ago benzinga.com
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX…
4 years ago pennystocks.com
3 High Volume Penny Stocks To Watch Before Next Week
Here's what you need to know about buying penny stocks on September 9th, 2022 The post 3 High Volume Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and…
-
4 years ago benzinga.com
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to…
-
4 years ago benzinga.com
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
4 years ago zacks.com
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?
Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
-
4 years ago benzinga.com
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 92 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 120 companies achieved new lows for the year.
4 years ago seekingalpha.com
Rubius: Poor Data, Punishing Environment, Beaten Stock
Rubius presented unconvincing data at AACR. The stock is down 80% in just 3 months.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows.
4 years ago globenewswire.com
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an…
4 years ago globenewswire.com
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 216 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
4 years ago globenewswire.com
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an…
4 years ago pennystocks.com
Here Are 3 Penny Stocks You Need to Know About in May 2022
Which penny stocks are you watching in May? The post Here Are 3 Penny Stocks You Need to Know About in May 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 466 companies hit new 52-week lows.
4 years ago benzinga.com
Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial
Rubius Therapeutics Inc (NASDAQ: RUBY) has announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors. Data were shared at the American…
4 years ago globenewswire.com
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an…
4 years ago prnewswire.com
RUBY PIPELINE FILES TO REORGANIZE UNDER CHAPTER 11 OF THE BANKRUPTCY CODE
HOUSTON , March 31, 2022 /PRNewswire/ -- Today, Ruby Pipeline, L.L.C. (Ruby), a natural gas pipeline joint venture between Kinder Morgan, Inc. (NYSE: KMI) and Pembina Pipeline Corporation (NYSE: PBA)…
4 years ago seekingalpha.com
Rubius Looks Attractive Before AACR Data Readout
Rubius Looks Attractive Before AACR Data Readout
4 years ago globenewswire.com
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday,…